Actualités Acasti Pharma Inc - ACST | Actions TSX Venture Exchange

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Acasti Pharma Reports Third Quarter 2023 Operational Results

Company to Host Conference Call Today at 1:00pm ET LAVAL, Québec, Feb. 14, 2023 (GLOBE NEWSWIRE...

Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule

LAVAL, Québec, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq:...

Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31

LAVAL, Québec, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq:...

Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18

LAVAL, Québec, Jan. 13, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq:...

Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures

LAVAL, Québec, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq:...

Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia

LAVAL, Québec, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq:...

Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)

LAVAL, Québec, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq:...

Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia

LAVAL, Québec, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”...

Acasti Pharma to Participate at the H.C. Wainwright 24th Annual Global Investment Conference

LAVAL, Québec, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Acasti Pharma Inc (ACST)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Acasti Pharma Inc (ACST) Actualités

Acasti Pharma Reports Third Quarter 2023 Operational Results

Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule

Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31

Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18

Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures

Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia

Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)

Acasti Pharma Reports Second Quarter 2023 Operational Results

Acasti Pharma to Present at Q4 Investor Summit

Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022

Acasti Announces Court Dismissal of Stockholder Litigation

Acasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders

Acasti Pharma to Participate in the Lytham Partners Fall 2022 Investor Conference

Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia

Acasti Pharma to Participate at the H.C. Wainwright 24th Annual Global Investment Conference

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Acasti Pharma Inc (ACST)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Acasti Pharma Inc (ACST) Actualités

Acasti Pharma Reports Third Quarter 2023 Operational Results

Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule

Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31

Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18

Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures

Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia

Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)

Acasti Pharma Reports Second Quarter 2023 Operational Results

Acasti Pharma to Present at Q4 Investor Summit

Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022

Acasti Announces Court Dismissal of Stockholder Litigation

Acasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders

Acasti Pharma to Participate in the Lytham Partners Fall 2022 Investor Conference

Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia

Acasti Pharma to Participate at the H.C. Wainwright 24th Annual Global Investment Conference

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Pourquoi rejoindre ADVFN?

Tout ce dont les traders professionnels ont besoin.

Supprimer les publicités